Ovato is indicated for the reduction of signs and symptoms and induction and maintenance of clinical remission in pediatric patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy (corticosteroids and/or aminosalicylate and/or an immunosuppressant). The safety and efficacy of Ovato is not established in patients less than 9 years of age.

Please refer to the Product Monograph at www.OVATOPM.ca for more information on conditions of clinical use, contraindications, warnings and precautions, adverse reactions, drug interactions, and dosing information.